Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In at $7.62 - I think this is way oversold at this point. 90% institutional ownership and the CEO himself put in over $1M of his own cash into this over the last 12 months, and at much higher PPS, I mind you. No way PDLI is going to die just like that. A bounce back to mid-$8's is quite likely following the news of the new accountant appointment next week.
$PDLI Janney Capital Remains Neutral On PDL Biopharma Following The Resign Of Ernst & Young http://www.smarteranalyst.com/2014/09/17/janney-capital-remains-neutral-on-pdl-biopharma-following-the-resign-of-ernst-young/
$PDLI Cowen Maintains Market Perform On PDL Biopharma Following 2Q14 Update; Raises PT To $8 http://www.smarteranalyst.com/2014/08/20/cowen-maintains-market-perform-on-pdl-biopharma-following-2q14-update-raises-pt-to-8/
Any longs out there with a strong opinion on the sustainability/growth of the new revenue stream they're putting together? Looks like they've been getting some lucrative deals, and if they can grow this model a little further as they re-develop a longer term, growing revenue stream... Thanks!
7:07AM PDL BioPharma prices $260.87 mln aggregate principal amount of its 4.00% Convertible Senior Notes due Feb 1, 2018 in an underwritten public offering (PDLI) 7.97 : The conversion rate of the Notes will initially be 109.1048 shares of common stock per $1,000 principal amount of the Notes equivalent to an initial conversion price of ~ $9.17 per share of common stock.
7:33AM PDL BioPharma provides $70 mln in financing to Durata Therapeutics (DRTX) (PDLI) 8.34 : Co announced that it closed a financing transaction with Durata Therapeutics (DRTX). Under the credit agreement, PDL will provide Durata with up to $70 million of debt financing with a five year term and will receive interest on the principal amount outstanding and a security interest in substantially all of Durata's assets.
7:00AM PDL BioPharma provides $60 mln in financing to LENSAR (PDLI) 8.08 : Co announced that it closed a financing transaction with LENSAR,in which PDL will provide LENSAR with up to $60 mln of debt financing, as part of an $87 mln total financing for LENSAR. The total financing of up to $60 mln was provided pursuant to a credit agreement that included an initial $40 mln in cash funded to LENSAR on October 1, 2013, and provides up to $20 mln in additional funds to LENSAR by September 30, 2014, upon the accomplishment of a specified milestone. In exchange, PDL received a security interest in all of LENSAR's assets and will receive interest on the principal amount outstanding.
Goldman-Sachs Conference Updates
Valuable remarks.. Annual-Global-Healthcare-Conference
Read here
PDLI does hang in there
it's been a good investment
Selling for tax reasons is still out there--this time because capital gains taxes are going up in January.
well PDLI is a love hate relationship
about the time you expect it to do well
it bites
and then when you don't, it surprises
4:07PM PDL BioPharma sees Q4 rev above consensus (PDLI) 7.45 -0.19 : Co issues upside guidance for Q4 (Dec), sees Q4 (Dec) revs of ~$86 mln vs. $78.82 mln Capital IQ Consensus. Revenue guidance for the fourth quarter of 2012 is net of an estimated payment due under the February 2011 settlement agreement with NVS. PDL pays to Novartis certain amounts based on net sales of Lucentis, made by Novartis, during calendar year 2011 and beyond. The amount paid is less than they receive in royalties on such sales.
Reported worldwide sales for Herceptin increased 15.2% in the third quarter of 2012 when compared to the same period in 2011. Ex-U.S. manufactured and sold Herceptin sales represented 35% of total Herceptin sales in the third quarter of 2012 as compared with 26% in the third quarter of 2011.
Reported worldwide sales for Lucentis increased 3% in the third quarter of 2012 when compared to the same period in 2011. All sales of Lucentis were from inventory produced in the United States. Reported worldwide sales for
Avastin sales increased 13% in the third quarter of 2012 when compared to the same period in 2011.
Oct. 8th, 2012; Eli Lilly made this important announcement on the Alzheimer medication Solanezumab, of which, if successful, PDL BioPharma will receive royalties from.
Mr. Funtleyder makes that assertion near the end of this video on Bloomberg.
http://us.rd.yahoo.com/finance/external/bloomberg/SIG=1335p4e22/*http://www.bloomberg.com/video/funtleyder-on-lilly-s-alzheimer-s-drug-nWW6TV~eTdmCZYnGfrGxjg.html?cmpid=yhoo
__________________________________________________________
"An experimental Alzheimer's treatment from Eli Lilly & Co. slowed memory loss by 42% in patients with a mild form of the memory-robbing disease in one drug trial and showed positive signs of doing so in another study, according to new data presented on Monday.
The results, although mixed, bolster hopes that a drug like Lilly's solanezumab could stymie Alzheimer's destructive march in patients in the early stage of the disease. Current therapies do nothing more than treat the symptoms. Yet more studies probably will be needed to reach a firm conclusion.
"Our next step is to talk to the regulators to see what this means, although we think this is a step forward in getting to a treatment for Alzheimer's," David Ricks, president of Lilly Bio-Medicines, said in an interview.
http://online.wsj.com/article/SB10000872396390444897304578044520966644406.html
buy one short another i like to say ;)
could happen
but the money to be made is in shorting it
this one goes higher IMO
because that's how I play this one
this dang company just keeps hanging in there and paying dividends
looks like the rating drop on PDLI had some effect
all while they keep churning out dividends
this just in my email
Ratings Change for PDL BioPharma Inc (PDLI):
Downgraded to REDUCE from HOLD on 4/23/12
I made the best money shorting it high and buying it low
it was either that or lose money
and that was the only way I could make decent money
especially after the courts totally 100% screwed them over
they won in the patent court
and then got royally screwed
I took a loss then and had enough of that
it's a great company imo
terrific
but the shorts just beat the living snot out of it
I decided to make money rather than lose money
A year is an awful long time to just be talking to no one, man. Took a small position here. Not shorting. We'll see.
PDL BioPharma Completes Regular Quarterly Dividend Payment
PR Newswire
INCLINE VILLAGE, Nev., March 14, 2012
INCLINE VILLAGE, Nev., March 14, 2012 /PRNewswire/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 14, 2012, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 7, 2012, the record date.
PDL BioPharma Provides First Quarter 2012 Royalty Revenue Guidance of $77 Million
we get up between $6.50 and $6.75
keep in mind it's a great shorting opportunity
~ Thursday! $PDLI ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $PDLI ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=PDLI&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=PDLI&p=W&b=3&g=0&id=p54550695994
~ Google Finance: http://www.google.com/finance?q=PDLI
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=PDLI#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=PDLI+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=PDLI
Finviz: http://finviz.com/quote.ashx?t=PDLI
~ BusyStock: http://busystock.com/i.php?s=PDLI&v=2
<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=PDLI >>>>>>
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
PDLI
New Rating REDUCE
Downgrade
Ratings Change for PDL Biopharma Inc (PDLI):
Downgraded to REDUCE from HOLD on 1/9/12
PDL BioPharma Provides Fourth Quarter 2011 Revenue Guidance of $72 Million
well they paid their dividend again
didn't get hit as hard this time it looks like
this stock is like owning a Dodge
it's a love hate relationship
PDL BioPharma Completes Regular Quarterly Dividend Payment
http://ih.advfn.com/p.php?pid=nmona&article=49186175&symbol=PDLI
well of course they did
they haven't missed one yet, even when they were called special dividends
Looks like it's time for me to short the living daylights
out of PDLI again
well haven't found anything anywhere else
on any buyout offer.
well watching PDLI for the last few minutes
I don't see much happening.....
still a lot of shorting and those big fish doing it
wouldn't put so much at risk......imo
has anyone else heard any rumors of a buyout offer for PDLI by a big Pharma?
it scared the poop out of me enough to cover my PDLI shorts
I'm kinda surprised I haven't seen anything else
but that's how it was with NDN, one day down as usual
and the next, whoompF! $20 a share....about gave me a heart attack
I doubt PDLI would go much past 12....but right now even getting caught shorting at $9-$10 would've flat out ruined me
if a serious offer happened.....
well that's about far enough....
think it's time to cover my PDLI shorts
PDL BioPharma Announces Second Quarter 2011 Financial Results
Pdl Biopharma, Inc. (MM) (NASDAQ:PDLI)
Intraday Stock Chart
Today : Thursday 28 July 2011
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2011.
Total revenues for the second quarter of 2011 were $122.1 million, compared to $120.3 million for the same period of 2010, a one percent year-over-year increase. Total revenues for the six months ended June 30, 2011, were $205.5 million, compared to $182.4 million for the same period of 2010. Included in results for the six months ended June 30, 2011, and not included in the same period in 2010, is a $10.0 million settlement payment from UCB Pharma S.A. resolving all legal disputes between the two companies. Excluding this one-time payment, revenue increased seven percent year over year for the six month period ended June 30, 2011.
Royalty revenues for the second quarter of 2011 are based on first quarter 2011 product sales by PDL's licensees. Revenue growth for the second quarter of 2011 over the same period in 2010 was primarily driven by increased first quarter 2011 sales by the Company's licensees of Herceptin®, which is marketed by Genentech and Roche; Lucentis®, which is marketed by Genentech and Novartis; and Tysabri®, which is marketed by Elan and Biogen Idec. Increases were offset, in part, by reduced royalties on sales of Avastin®. PDL received royalties for these product sales in the second quarter of 2011. The second quarter royalty payment received from Genentech included royalties generated on all worldwide sales.
Total general and administrative expenses for the second quarter of 2011 were $3.8 million, compared with $8.8 million for the same period of 2010. Total general and administrative expenses for the six months ended June 30, 2011, were $9.6 million, compared to $18.2 million for the same period in 2010. The decrease in the general and administrative expenses for both the quarter and six month period ended June 30, 2011, was primarily driven by decreases in legal and professional services expenses. The decrease in legal expense is a result of the conclusion of several legal matters in the first quarter of 2011. The decrease in professional services expense resulted from reduced costs associated with one-time special project costs.
Total non-operating expense, net, for the three months ended June 30, 2011, was $10.4 million as compared with $27.8 million for the same period in 2010. In the three months ended June 30, 2011, PDL redeemed $133.5 million of its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes), at 100.29 percent of face value that resulted in a loss on repurchase of $0.8 million. In the three months ended June 30, 2010, PDL repurchased $84.2 million of its 2.75% Convertible Subordinated Notes due August 16, 2023, at a 19 percent premium which resulted in a loss on repurchase of $16.3 million. The reduction in interest expense is primarily attributable to partial repayment of PDL's QHP PhaRMA(SM) Senior Secured Notes due March 15, 2015, for which the current principal balance at June 30, 2011, was $141.7 million as compared with $249.6 million at June 30, 2010.
Net income for the second quarter of 2011 was $70.0 million, or $0.38 per diluted share, as compared with net income of $50.1 million, or $0.30 per diluted share, for the same period of 2010. Net income for the six months ended June 30, 2011, was $114.5 million, or $0.63 per diluted share compared to $76.1 million, or $0.44 per diluted share, for the same period in 2010. Adjusting for the convertible note repurchase transactions described above and the amortization of the non-cash debt discount accounting treatment for the 3.75% Convertible Senior Notes due May 1, 2015 (the May 2015 Notes), non-GAAP net income for the second quarter of 2011 was $70.8 million, or $0.39 per diluted share, compared with $64.9 million, or $0.38 per diluted share, in the second quarter of 2010. Non-GAAP net income for the six months ended June 30, 2011, was $115.4 million, or $0.63 per diluted share, compared with $90.9 million, or $0.52 per diluted share in the six months ended June 30, 2010.
Net cash provided by operating activities in the six months ended June 30, 2011, was $87.9 million, compared with $123.6 million net cash provided by operating activities for the six months ended June 30, 2010. At June 30, 2011, PDL had cash, cash equivalents and investments of $236.3 million, compared with $248.2 million at December 31, 2010.
RECENT DEVELOPMENTS
2012 Notes Redemption and Issuance of $155.25 Million of May 2015 Notes
On May 16, 2011, we issued $155.25 million in aggregate principal amount of the May 2015 Notes in an underwritten public offering. The May 2015 Notes were issued at an initial conversion ratio of 126.2985 shares of the Company's common stock per $1,000 principal amount of the May 2015 Notes, or a conversion price of approximately $7.92 per share. The conversion ratio was subsequently adjusted to 129.2740 shares of the Company's common stock per $1,000 of principal amount, or a conversion price of approximately $7.74 per share, in connection with the cash dividend paid on June 15, 2011. The May 2015 Notes are convertible on or after November 1, 2014 or upon the occurrence of certain conditions as described in the indenture. If a conversion occurs, to the extent that the conversion value exceeds the principal amount, the principal amount is due in cash and the difference between the conversion value and the principal amount is due in shares of common stock.
Concurrent with the issuance of the May 2015 Notes, the Company entered into privately negotiated purchased call options for the Company's common stock. The purchased call options transactions cover, subject to customary anti-dilution adjustments, the number of shares of the Company's common stock that underlie the May 2015 Notes and are intended to reduce the dilutive impact of the conversion feature of the May 2015 Notes. To reduce the hedging costs of the purchased call options, the Company also entered into privately negotiated warrant transactions with the hedge counterparties relating to the same number of shares of the Company's common stock. The warrant transactions could have a dilutive effect to the extent that the market price per share of the Company's common stock exceeds the applicable strike price of the warrants on any expiration date of the warrants.
On June 30, 2011, using the proceeds from the issuance of the May 2015 Notes, we redeemed the remaining $133.5 million in aggregate principal of our 2012 Notes at a redemption price of 100.29 percent of face value for aggregate consideration of $133.9 million plus accrued but unpaid interest of $1.0 million. With the completion of this redemption on June 30, 2011, the 2012 Notes were fully retired.
Adjustments to Convertible Note Conversion Ratios
In connection with the dividend payment on June 15, 2011, the conversion ratios for our convertible notes were increased. The conversion ratios for each of our 2012 Notes (which were redeemed in full on June 30, 2011) and our 2.875% Convertible Senior Notes due February 15, 2015 (the 2015 Notes), were adjusted to 147.887 shares of common stock per $1,000 principal amount, or a conversion price of approximately $6.76 per share, effective June 9, 2011. The conversion ratio for our May 2015 Notes was adjusted to 129.2740 shares of common stock per $1,000 principal amount, or a conversion price of approximately $7.74 per share, effective June 6, 2011. The conversion ratios for each of the 2012 Notes and the 2015 Notes was previously 144.474 shares of common stock per $1,000 principal amount, or a conversion price of approximately $6.92 per share. The conversion ratio for the May 2015 Notes was previously 126.2985 shares of common stock per $1,000 principal amount, or a conversion price of approximately $7.92 per share.
Dividend Payment
On February 25, 2011, our board of directors adopted a regular, quarterly dividend policy and declared that the quarterly dividends to be paid to our stockholders in 2011 will be $0.15 per share of common stock. The dividends are payable on March 15, June 15, September 15 and December 15 of 2011 to stockholders of record on March 8, June 8, September 8 and December 8 of 2011, the record dates for each of the dividend payments, respectively. On each of March 15 and June 15, 2011, we paid the quarterly dividend to our stockholders of $21.0 million using earnings generated in the first six months of 2011 and cash on hand.
Genentech and Roche Dispute
In August 2010, we received a letter from Genentech, sent on behalf of Roche and Novartis, asserting that Avastin, Herceptin, Lucentis and Xolair® (the Genentech Products) do not infringe our supplementary protection certificates (SPCs) granted to us by various countries in Europe for each of the Genentech Products and seeking a response to these assertions. The SPCs covering the Genentech Products effectively extend the patent protection for our European Patent No. 0 451 216B until December 2014, except that the SPCs for Herceptin will generally expire in July 2014. We responded to Genentech, stating that we believe its assertions of non-infringement are without merit and that we disagreed fundamentally with its assertions of non-infringement with respect to the Genentech Products. In August 2010, we filed a complaint in the Second Judicial District of Nevada, Washoe County, against Genentech and Roche seeking to enforce our rights under our 2003 settlement agreement with Genentech and an order from the court declaring that Genentech is obligated to pay royalties to us on sales of the Genentech Products that are manufactured and sold outside of the United States.
On July 7, 2011, the Second Judicial District Court of Nevada ruled in favor of PDL on two motions to dismiss filed by Genentech and Roche in this lawsuit. The court denied Genentech and Roche's motion to dismiss four of PDL's five claims for relief and, further, denied Roche's separate motion to dismiss for lack of personal jurisdiction. The court dismissed one of PDL's claims that Genentech committed a bad-faith breach of the covenant of good faith and fair dealing stating that, based on the current state of the pleadings, no "special relationship" had been established between Genentech and PDL, as required under Nevada law.
The effect of the Court's ruling is that PDL is permitted to continue to pursue its claims that (i) Genentech is obligated to pay royalties to PDL on international sales of the Genentech Products; (ii) Genentech, by challenging, at the behest of Roche and Novartis, whether PDL's SPCs cover the Genentech Products breached its contractual obligations to PDL under the 2003 settlement agreement; (iii) Genentech breached the implied covenant of good faith and fair dealing with respect to the 2003 settlement agreement and (iv) Roche intentionally and knowingly interfered with PDL's contractual relationship with Genentech in conscious disregard of PDL's rights.
PDL seeks compensatory damages, including liquidated damages and other monetary remedies set forth in the 2003 settlement agreement, punitive damages and attorney's fees as a result of Genentech and Roche's conduct. The ultimate outcome of this litigation is uncertain and we may not be successful in our allegations.
Revenue Guidance for 2011
As previously announced, PDL will continue to provide revenue guidance for each quarter in the third month of that quarter. Third quarter 2011 revenue guidance will be provided in early September.
Conference Call Details
PDL will hold a conference call to discuss financial results at 4:30 p.m. ET today, July 27, 2011. To access the live conference call via phone, please dial (877) 556-5921 from the United States and Canada or (617) 597-5474 internationally. The conference ID is 50762453. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through August 3, 2011, and may be accessed by dialing (888) 286-8010 from the United States and Canada or (617) 801-6888 internationally. The replay passcode is 81465883.
To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
http://ih.advfn.com/p.php?pid=nmona&article=48594598&symbol=PDLI
Pipelines and Patents Continue to Drive the Biotech Sector
http://investorshub.advfn.com/boards/post_new.aspx?board_id=12267
and it's been on a tear lately
still wondering why one of the big Pharma's just doesn't make the move to buy out PDLI
figure as soon as I short a huge pile of PDLI
an announcement will come out saying Roche or one of them is buying
it at $12 a share and I'd lose my arse
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
228
|
Created
|
03/31/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |